Eli Lilly (NYSE: LLY) is part of this group. On Sept. 16, the drugmaker announced plans to build a $5 billion facility in ...

Drugmaker Eli Lilly said Tuesday it is pausing its trial of a combination antibody treatment for coronavirus for safety reasons. Usually, clinical trials are paused because a volunteer has suffered a ...

In today’s ACT Brief, we explore how Eli Lilly’s orforglipron could become the first oral GLP-1 therapy reviewed under FDA’s new national priority program, and examine emerging regulatory and ethical ...

The U.S. government has stopped its distribution of Eli Lilly’s COVID-19 antibody bamlanivimab alone, saying that the increasing emergence of coronavirus variants has made the treatment ineffective, ...

WASHINGTON (AP) – Independent monitors have paused enrollment in a study testing the COVID-19 antiviral drug remdesivir plus an experimental antibody therapy being developed by Eli Lilly that’s ...

The U.S. has halted shipping Eli Lilly’s COVID-19 antibody cocktail because of analyses showing it’s ineffective against virus variants, The Wall Street Journal reported. HHS said June 25 it is ...

This is an archived article and the information in the article may be outdated. Please look at the time stamp on the story to see when it was last updated. Drugmaker Eli Lilly said Thursday its ...

The drug, which Lilly in-licensed four years ago and is designed to inhibit a protein known as P2X7, did not meet the company ...

Eli Lilly & Company (NYSE:LLY) ranks among the best fundamental stocks to buy right now. Eli Lilly & Company (NYSE:LLY) revealed plans on September 16 to build a $5 billion manufacturing facility in ...

Sept 16 (Reuters) - Eli Lilly and Co (LLY.N), opens new tab on Wednesday said a single infusion of its experimental antibody treatment reduced the need for hospitalization and emergency room visits ...

"Eli Lilly buys Adverum in eye disease gene therapy punt" was originally created and published by Pharmaceutical Technology, ...

Before being discontinued, the P2X7 receptor blocker had cleared a master protocol study in chronic pain, though Eli Lilly ...